IP Library › Granted Patent US 9,631,015
Granted Patent B2
US 9,631,015 · App. 14/795,374 · Granted Apr 25, 2017

Methods for treating IL-6 mediated diseases with antibody molecules specific for IL-6

Inventors: Richard Evan Gelinas (Seattle, WA); Mitra Choudhury Singhal (Seattle, WA); Yi Zhang (Palo Alto, CA); Andrew George Popplewell (Slough, GB); Ralph Adams (Slough, GB)
Assignee: UCB Pharma S.A.
C07K16/248A61K2039/505C07K2316/96C07K2317/24C07K2317/34C07K2317/54C07K2317/55C07K2317/565C07K2317/73C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,631,015
App. No.
14/795,374
Granted
Apr 25, 2017
Kind
B2
Abstract

The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Claims (7)

1. A method of treating a human or animal subject suffering from a disorder mediated by IL-6, the method comprising administering to the subject an effective amount of an antibody comprising a heavy chain comprising a sequence comprising SEQ ID NO:16 and a light chain comprising a sequence comprising SEQ ID NO:18.

2. A method of treating a human or animal subject suffering from a disorder mediated by IL-6, the method comprising administering to the subject an effective amount of an antibody comprising a heavy chain comprising a sequence comprising SEQ ID NO:11 and a light chain comprising a sequence comprising SEQ ID NO:13.

3. A method of treating an animal subject suffering from a disorder mediated by IL-6, the method comprising administering to the subject an effective amount of an antibody comprising a heavy chain variable region comprising a sequence comprising SEQ ID NO:2, and a light chain variable region comprising a sequence comprising SEQ ID NO:4.

4. The method of any one of claims 1 - 3 , wherein the disorder is an inflammatory or autoimmune disorder.

5. The method of claim 4 , wherein the disorder is an inflammatory disease.

6. The method of claim 4 , wherein the disorder is rheumatoid arthritis or systemic lupus erythematosus (SLE).

7. The method of claim 4 , wherein the disorder is multiple sclerosis or Guillain-Barr syndrome.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2022
From: UCB PHARMA SA
To: R-PHARM INTERNATIONAL LLC
Reel/Frame 059151/0908 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2016
From: UCB S.A.
To: UCB PHARMA S.A.
Reel/Frame 038264/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2016
From: GELINAS, RICHARD EVAN; SINGHAL, MITRA CHOUDHURY; ZHANG, YI; POPPLEWELL, ANDREW GEORGE; ADAMS, RALPH
To: UCB S.A.
Reel/Frame 038249/0866 →
Continuity (5)
Continuation 13928458 · Jun 27, 2013
Continuation 13288260 · Nov 3, 2011
Division 11608408 · Dec 8, 2006
Provisional Application 60748926 · Dec 9, 2005
Related Publication 20160039929A1 · Feb 11, 2016